In Good Company with Nicolai Tangen - HIGHLIGHTS: Vasant Narasimhan - CEO of Novartis
Episode Date: June 27, 2025We've curated a special 10-minute version of the podcast for those in a hurry. Here you can listen to the full episode: https://podcasts.apple.com/no/podcast/novartis-ceo-medical...-innovation-tech-partnerships-and/id1614211565?i=1000714438745&l=nb Can AI help us find cures for diseases we've never been able to treat? Nicolai Tangen speaks with Vasant 'Vas' Narasimhan, CEO of Novartis, about pioneering pharmaceutical innovation. They explore breakthrough cell and gene therapies, AI partnerships with leading tech companies, and how Novartis transformed from a sprawling conglomerate into a streamlined drug discovery company. Vas shares his unique perspective as a physician-scientist turned CEO, his concerns about Europe's declining pharma competitiveness, and his leadership philosophy of being the 'chief energy officer.' With €235 billion in market cap and groundbreaking treatments reaching patients worldwide, Novartis continues unlocking medical breakthroughs. Tune in!In Good Company is hosted by Nicolai Tangen, CEO of Norges Bank Investment Management. New full episodes every Wednesday, and don't miss our Highlight episodes every Friday.The production team for this episode includes Isabelle Karlsson and PLAN-B's Niklas Figenschau Johansen, Sebastian Langvik-Hansen and Pål Huuse. Background research was conducted by Isabelle Karlsson.Watch the episode on YouTube: Norges Bank Investment Management - YouTubeWant to learn more about the fund? The fund | Norges Bank Investment Management (nbim.no)Follow Nicolai Tangen on LinkedIn: Nicolai Tangen | LinkedInFollow NBIM on LinkedIn: Norges Bank Investment Management: Administrator for bedriftsside | LinkedInFollow NBIM on Instagram: Explore Norges Bank Investment Management on Instagram Hosted on Acast. See acast.com/privacy for more information.
Transcript
Discussion (0)
Hi, everybody. Tune into this short version of the podcast, which we do every Friday.
For the long version, tune in on Wednesdays.
Hi, everyone. I'm Nicolai Tangen, the CEO of the Norwegian Sovereign Wealth Fund. And
today I'm in really good company with Vaz Narasiman, the CEO of Novartis. Vaz has one
of the most fascinating backgrounds in pharma. He is a trained physician who also worked in the front lines,
fighting tuberculosis and malaria in developing countries before rising to
lead one of the world's largest pharmaceutical companies.
We own 2.3% of Novartis and that's worth more than $5 billion, roughly
10,000 Norwegian grown-up per Norwegian citizen.
So Vaz, big thanks for joining us.
Great to be here, Nikolai.
Just briefly to kick off, for those who are not familiar with Novartis,
in 10 seconds, just what are your areas of focus?
Yeah, we're one of the largest biopharmaceutical companies in the world, focused on innovative
medicines in oncology, cardiovascular disease, neuroscience, and immunological diseases.
Now, you have a different background compared to many other pharma CEOs.
How do you think that has shaped your approach to leading Novartis?
Well, I think it's helped in many dimensions.
I mean, coming from being a physician, coming from a scientific background,
I'm definitely steeped in the R&D elements
of the work we do.
So I'm always thinking about the medicine,
how the medicines impact patients, very data driven,
always thinking about how these medicines
might fit into clinical practice.
And given that the core of what a biopharmaceutical company
does is find breakthrough innovations
that matter for patients in the long run,
I think it's a really helpful background.
And I had to learn a lot about business.
I didn't go to business school.
I had to learn all of the ins and outs of capital allocations and balance sheets,
P and Ls running, running businesses.
But I think the combination of a medical background and business
background has served me well.
Yeah, absolutely.
Absolutely.
Well, to be frank, business is, is not so difficult compared to medicine.
Well, we're, we're living in a, we are living at a time where there are more miracles than normal because
of the way science is moving, right? So when you look at everything you are involved with,
what are the most significant scientific breakthroughs on the horizon that you are
excited about? Yeah, I think a couple of things, and they range across a whole spectrum.
I think on one part in terms of population health,
our ability to intervene earlier and earlier in disease
to hopefully prevent diseases
from even getting to later stages,
I think will be incredibly important.
Demography in the world is only getting more challenging,
huge aging populations, healthcare systems under strain, not enough young people always with the fertility rate falling to actually
fund these healthcare systems.
So we're going to have to prevent disease.
In our experiences, you can go earlier, we're working very hard to find how can you intervene
earlier and earlier in various cancers.
We just had another important data set in prostate cancer intervening early. And the idea is how can you intervene so that the cancer
doesn't get to a stage where ultimately requires hospitalizations. So I think
early intervention is a huge area of focus. I think another exciting area
clearly is the idea of can you completely reset diseases. This all comes
out of the world of cell and gene therapies where we already learned that
for certain genetic diseases, and Novartis is one of the leaders here, we're able to
almost deliver a cure or a dramatic response by using the gene therapies to actually replace
a gene in the body.
So now what we've learned, and there's actually data coming out just this week, that you can
actually use cell therapy to reset the immune system.
And there's a whole range of immunological diseases that are very severe, affecting young
people and old people.
And the idea here is with these therapies, using cell therapy, you can reset the immune
system and turn back the clock on their disease by 15 or 20 years.
And so this is, I think, a staggering innovation that will change
the lives of, hopefully over time, millions and millions of people.
Moving on, AI and digital, you really have been a champion in the
digital transformation in pharma. Now, you mentioned briefly in the
beginning some of the digital initiatives, but what would you say are
the most important ones that you have?
I think clearly AI's impact in research and development in our industry
will likely have the longest lasting impact.
There's a lot that's happening in operations, manufacturing, supply chain, finance,
and that I think is important, clearly having an impact already,
but ultimately will become, I think, standard
across our sector and other sectors.
The biggest question here is can you use AI
to either discover what is a drug target,
so think of it as the key lock that we need to unlock,
so find those key locks,
and then can you also use AI to optimize the key
into the lock so that that key can ultimately unlock
the biological process that we're talking about.
Now as to where we are today, we're already using AI with Isomorphic Labs, the Google
DeepMind company, other partners to optimize those keys.
So we have some ideas for the keys.
AI takes all of the information known out there and inside the company and optimize those candidate drugs
and then helps us speed up the process
by predicting how it will ultimately do
in preclinical safety, toxicology,
in terms of its pharmacokinetics, its manufacturability.
That process is now, and that's really happening now
at scale in companies like ours and at other companies.
And I think that will hopefully shorten the early drug development process by years.
And that's, I think, really exciting.
And then the bigger question is, could you actually unlock biological processes with
AI and actually understand?
And that I think we're further away from.
So you work with Microsoft, Palantir, but you mentioned the isomorphic labs which is
Hasabe's venture, right? You've got the Nobel Prize inside Google. Just how
do you work with them? What do they do for you? Yeah, so it's a very, I think
we're one of their two partners and basically what we do is we give them
again to take the key lock and the key analogy.
We give them some locks that we know
or we hypothesize are very important
in diseases like cancer or heart disease
that we simply have not been able to drug
or IE find the key for.
And we say we've struggled with our traditional methods.
Can AI, can their capabilities ultimately enable us
to find those keys?
And so what they do is they use AI to design new drugs.
What's been very interesting is AI comes up with drug structures that we've not thought about or really explored.
And so we're starting to see the early results.
I think we now have over six different projects going with them and hopefully to expand more into the future.
And we'll see if AI can solve
what we call our undruggable targets.
So can the AI help us drug the undruggable?
That's the question.
So Vars, I'm giving you this magic wand.
You can change three things in European pharma.
What would you change?
I would say that we should have a European wide
list price system that then countries can
adjust based on GDP per capita that then gives us a framework for list prices
across Europe. I think second there should be no allow allowance for capping
growth of the pharmaceutical sector. So basically like if you take a country
like Italy, our entire growth in Italy is paid back to Italy at the end of the year.
And so it's very hard to grow a business if you're always paying back your growth to the
many countries out there.
So we've got to end this practice.
And then third, I think Europe has to end also its practice of propping up the generics
industry.
Go to the US model where we have high innovation
and then generics prices that are the lowest in the world.
And then you will find the fiscal space to invest in innovation.
These are three, I think, very doable changes.
We wrote about it in the Financial Times and let's see.
You mentioned also your own physical health and so on, just nutrition and what are the
kind of things you are particularly...
Oh yeah.
Yeah.
So look, I got taught very early on from my coach that I work with today, his name is
Scott Pelton, this approach, mindset, movement, nutrition and recovery, and I stick with it.
So mindset, clearly mindfulness, meditation, observing yourself, observing why you
think the things you think, why you feel the things you do and then setting
yourself up in the right mindset each day and for each interaction or each
moment even when I have to show up on the In Good Company podcast. You know
nutrition, you know I think you have to think why do you eat the things you eat
and how you eat will affect your performance even in small ways.
So something I always think about.
Obviously movement, I mean exercise has a lot of impact on the nervous system.
Over the years I've learned that exercise can reset your sympathetic and parasympathetic
nervous system.
By the way, so much of leadership comes down to managing your nervous system.
You're likely not going to make a good decision when you're on high sympathetic drive. When you're more balanced, parasitic,
sympathetic, you're more likely to get all the inputs that you need. So observing
that in yourself is hugely important. And then recovery, I've learned over
the years the power of sleep. I mean I'm obsessed with trying to optimize my
sleep. I've got, you know, technology, sleep technology, sleep supplements, all kinds of things to really say
How can I get seven plus hours of very high quality sleep and recover and all of those things
compound over time and then give you the energy.